Second-generation antipsychotics: looking beyond efficacy.
Awad
A George
AG
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D019964:Mood Disorders / Q000139:chemically induced* / Q000378:metabolism; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D004298:Dopamine